Table 1. Open in new tab Biochemical...

	P-Ca, mmol/L	P-Ca ion, mmol/L	P-P_i, mmol/L	P-PTH, ng/L	P-ALP, U/L	25OHD, nmol/L	1,25(OH)₂D₃, pmol/L	P-Cr, μmol/L	U-Ca/Cr	BMD Z-Score
Reference range	2.05–2.70	1.16–1.30	1.10–1.80	8–73	115–460	>40	63–228	10–76	<0.6
Before treatment
1 y, 7 mo	2.99		1.39	22	386			44
6 y, 3 mo	3.02	1.43	0.72	51	361	32	96	28	0.04
8 y, 2 mo	2.81	1.46	1.10	72	182	20	110	30	<0.17
9 y, 6 mo	2.79	1.51	1.04	70	186	44	116	32	<0.13	−3.0	−0.3	−1.0	−0.3
Treatment with cinacalcet (starting at 10 y)
10 y, 3 mo	2.66	1.40	1.14	43				38	0.07
10 y, 6 mo	2.33	1.23	1.39	34					0.09
10 y, 10 mo	2.17	1.17	1.32	16	189	41	105		<0.15	−2.3	−0.5	−1.0	−1.3
12 y, 4 mo		1.22	1.16	69	266	58		45	0.13	−2.5	−1.0	−1.3	−2.0
13 y, 5 mo		1.38	1.10	64	290	53		58	<0.09	−2.0	−1.4	−1.7	−1.8
After treatment
13 y, 10 mo		1.45	0.99	75	262	198			0.02
14 y, 4 mo		1.42	0.83	56	183	43	221		<0.07
15 y, 4 mo	2.87	1.47	1.06		187	46	207		0.06

P-Ca, mmol/L

P-Ca ion, mmol/L

P-P_i, mmol/L

P-PTH, ng/L

P-ALP, U/L

25OHD, nmol/L

1,25(OH)₂D₃, pmol/L

P-Cr, μmol/L

U-Ca/Cr

BMD Z-Score

Reference range

2.05–2.70

1.16–1.30

1.10–1.80

8–73

115–460

>40

63–228

10–76

<0.6

Before treatment

1 y, 7 mo

2.99

1.39

386

6 y, 3 mo

3.02

1.43

0.72

361

0.04

8 y, 2 mo

2.81

1.46

1.10

182

110

<0.17

9 y, 6 mo

2.79

1.51

1.04

186

116

<0.13

−3.0

−0.3

−1.0

−0.3

Treatment with cinacalcet (starting at 10 y)

10 y, 3 mo

2.66

1.40

1.14

0.07

10 y, 6 mo

2.33

1.23

1.39

0.09

10 y, 10 mo

2.17

1.17

1.32

189

105

<0.15

−2.3

−0.5

−1.0

−1.3

12 y, 4 mo

1.22

1.16

266

0.13

−2.5

−1.0

−1.3

−2.0

13 y, 5 mo

1.38

1.10

290

<0.09

−2.0

−1.4

−1.7

−1.8

After treatment

13 y, 10 mo

1.45

0.99

262

198

0.02

14 y, 4 mo

1.42

0.83

183

221

<0.07

15 y, 4 mo

2.87

1.47

1.06

187

207

0.06

	P-Ca, mmol/L	P-Ca ion, mmol/L	P-P_i, mmol/L	P-PTH, ng/L	P-ALP, U/L	25OHD, nmol/L	1,25(OH)₂D₃, pmol/L	P-Cr, μmol/L	U-Ca/Cr	BMD Z-Score
Reference range	2.05–2.70	1.16–1.30	1.10–1.80	8–73	115–460	>40	63–228	10–76	<0.6
Before treatment
1 y, 7 mo	2.99		1.39	22	386			44
6 y, 3 mo	3.02	1.43	0.72	51	361	32	96	28	0.04
8 y, 2 mo	2.81	1.46	1.10	72	182	20	110	30	<0.17
9 y, 6 mo	2.79	1.51	1.04	70	186	44	116	32	<0.13	−3.0	−0.3	−1.0	−0.3
Treatment with cinacalcet (starting at 10 y)
10 y, 3 mo	2.66	1.40	1.14	43				38	0.07
10 y, 6 mo	2.33	1.23	1.39	34					0.09
10 y, 10 mo	2.17	1.17	1.32	16	189	41	105		<0.15	−2.3	−0.5	−1.0	−1.3
12 y, 4 mo		1.22	1.16	69	266	58		45	0.13	−2.5	−1.0	−1.3	−2.0
13 y, 5 mo		1.38	1.10	64	290	53		58	<0.09	−2.0	−1.4	−1.7	−1.8
After treatment
13 y, 10 mo		1.45	0.99	75	262	198			0.02
14 y, 4 mo		1.42	0.83	56	183	43	221		<0.07
15 y, 4 mo	2.87	1.47	1.06		187	46	207		0.06

Table 1.

Open in new tab

Biochemical Parameters and BMD Measurements Before, During, and After Cinacalcet Treatment

	P-Ca, mmol/L	P-Ca ion, mmol/L	P-P_i, mmol/L	P-PTH, ng/L	P-ALP, U/L	25OHD, nmol/L	1,25(OH)₂D₃, pmol/L	P-Cr, μmol/L	U-Ca/Cr	BMD Z-Score
	P-Ca, mmol/L	P-Ca ion, mmol/L	P-P_i, mmol/L	P-PTH, ng/L	P-ALP, U/L	25OHD, nmol/L	1,25(OH)₂D₃, pmol/L	P-Cr, μmol/L	U-Ca/Cr	LS	FH	FN	WB
Reference range	2.05–2.70	1.16–1.30	1.10–1.80	8–73	115–460	>40	63–228	10–76	<0.6
Before treatment
1 y, 7 mo	2.99		1.39	22	386			44
6 y, 3 mo	3.02	1.43	0.72	51	361	32	96	28	0.04
8 y, 2 mo	2.81	1.46	1.10	72	182	20	110	30	<0.17
9 y, 6 mo	2.79	1.51	1.04	70	186	44	116	32	<0.13	−3.0	−0.3	−1.0	−0.3
Treatment with cinacalcet (starting at 10 y)
10 y, 3 mo	2.66	1.40	1.14	43				38	0.07
10 y, 6 mo	2.33	1.23	1.39	34					0.09
10 y, 10 mo	2.17	1.17	1.32	16	189	41	105		<0.15	−2.3	−0.5	−1.0	−1.3
12 y, 4 mo		1.22	1.16	69	266	58		45	0.13	−2.5	−1.0	−1.3	−2.0
13 y, 5 mo		1.38	1.10	64	290	53		58	<0.09	−2.0	−1.4	−1.7	−1.8
After treatment
13 y, 10 mo		1.45	0.99	75	262	198			0.02
14 y, 4 mo		1.42	0.83	56	183	43	221		<0.07
15 y, 4 mo	2.87	1.47	1.06		187	46	207		0.06

	P-Ca, mmol/L	P-Ca ion, mmol/L	P-P_i, mmol/L	P-PTH, ng/L	P-ALP, U/L	25OHD, nmol/L	1,25(OH)₂D₃, pmol/L	P-Cr, μmol/L	U-Ca/Cr	BMD Z-Score
	P-Ca, mmol/L	P-Ca ion, mmol/L	P-P_i, mmol/L	P-PTH, ng/L	P-ALP, U/L	25OHD, nmol/L	1,25(OH)₂D₃, pmol/L	P-Cr, μmol/L	U-Ca/Cr	LS	FH	FN	WB
Reference range	2.05–2.70	1.16–1.30	1.10–1.80	8–73	115–460	>40	63–228	10–76	<0.6
Before treatment
1 y, 7 mo	2.99		1.39	22	386			44
6 y, 3 mo	3.02	1.43	0.72	51	361	32	96	28	0.04
8 y, 2 mo	2.81	1.46	1.10	72	182	20	110	30	<0.17
9 y, 6 mo	2.79	1.51	1.04	70	186	44	116	32	<0.13	−3.0	−0.3	−1.0	−0.3
Treatment with cinacalcet (starting at 10 y)
10 y, 3 mo	2.66	1.40	1.14	43				38	0.07
10 y, 6 mo	2.33	1.23	1.39	34					0.09
10 y, 10 mo	2.17	1.17	1.32	16	189	41	105		<0.15	−2.3	−0.5	−1.0	−1.3
12 y, 4 mo		1.22	1.16	69	266	58		45	0.13	−2.5	−1.0	−1.3	−2.0
13 y, 5 mo		1.38	1.10	64	290	53		58	<0.09	−2.0	−1.4	−1.7	−1.8
After treatment
13 y, 10 mo		1.45	0.99	75	262	198			0.02
14 y, 4 mo		1.42	0.83	56	183	43	221		<0.07
15 y, 4 mo	2.87	1.47	1.06		187	46	207		0.06

Abbreviations: FH, femoral head; FN, femoral neck; LS, lumbar spine; 25OHD, serum concentration of 25OHD; 1,25(OH)₂D₃, serum concentration of 1,25(OH)₂D₃; P-ALP, plasma alkaline phosphatase; P-Ca, plasma calcium; P-Cr, plasma creatinine; P-P_i, plasma inorganic phosphate; U-Ca/Cr, urine calcium/creatinine ratio; WB, whole body.

This Feature Is Available To Subscribers Only